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Abstract 
 
                                                                                       
in vivo fate of nanoparticles made of the squalene-gemcitabine prodrug and two novel 
derivatives of squalene with the cyanine dyes 5.5 and 7.5, which behave as efficient 
FRET pair in the NIR region. Following intravenous administration, nanoparticles 
initially accumulate in the liver, then they show loss of their integrity within 2 h and 
clearance of the squalene bioconjugates is observed within 24 h. Such awareness is a key 
prerequisite before introduction into clinical settings. 
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The use of nanotechnology-based medicines (i.e., nanomedicines) for drug delivery holds the 
potential to overcome limits associated to conventional chemotherapies (e.g., non-specific 
biodistribution, metabolization, rapid excretion), thus providing a solution to various medical 
challenges.
[1]
 Although the major advances have been done in the field of cancer, 
nanomedicines may also be beneficial in several other therapeutic areas by providing an 
increase in the drug therapeutic index.
[2]
 Generally, drugs are physically encapsulated into the 
nanocarrier, but the design of prodrug-based nanomedicines has also emerged as alternative 
strategy. This approach enabled to face drawbacks such as (i) the low drug loading generally 
achieved with physical encapsulation processes and (ii) the uncontrolled drug release (i.e., 
“burst release”), corresponding to that fraction of the drug only adsorbed onto the nanocarrier 
surface.
[3]
 
In this context, terpene-based prodrug nanoparticles (NPs) have been proposed by our group a 
few years ago.
[4]
 Among them, the biocompatibility of squalene (SQ) (a natural lipid, 
intermediate in the cholesterol biosynthesis) promoted its large investigation as drug carrier, 
and allowed the design of a small library of bioconjugates by covalent conjugation of various 
drug molecules to squalene (i.e., the so-called “squalenoylation approach”).[5] All these 
bioconjugates demonstrated the capacity to spontaneously self-assemble in aqueous solution 
as nanoparticles, without requiring any other carrier material. The most extensive 
investigation has been performed with nanoparticles made of the bioconjugate in which the 
squalene is linked to gemcitabine (SQGem) (Figure 1), a nucleoside analogue clinically 
indicated in the treatment of various solid tumors. Despite promising results in a series of 
experimental tumor models,
[6]
 any further step toward a clinical investigation of these SQGem 
NPs has been hindered, up to now, by the lack of clear knowledge on their fate after 
intravenous administration. In particular, the appreciation of liver accumulation, the major 
organ of nanoparticles distribution, is of outmost importance before the first human use. 
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Indeed liver overload of nanoparticulate material may induce insurgence of severe liver injury 
and irreversible impairment of its functionality.
[7]
 
In order to face this issue, we have monitored in this study the in vivo fate of    e    s 
ta ing ad antage of the   rster resonance energy transfer      ) principle, a non-radiative 
process, which relies on the transfer of energy from an excited molecule (i.e., donor, D) to an 
acceptor one (i.e., acceptor, A) closely located.
[8]
 The strong dependency of FRET from the 
distance between the FRET pair (1-10 nm) has made this technique extremely appealing to 
monitor biological phenomena,
[9]
 integrity of nanoparticles
[10]
 and micelles,
[11]
 but to our 
knowledge, it had not found application yet to follow the in vivo integrity of nanomedicines 
with an already demonstrated therapeutic efficacy. To reach this goal two new lipophilic 5.5 
and 7.5 cyanine dyes bearing a squalene appendage tethered to the benzo[e]indol‐ 3‐ ium 
moiety through a six-carbon linker have been synthetized (SQCy5.5 and SQCy7.5) (Figure 
1). First, following established protocols for the synthesis of asymmetrically substituted 
cyanines,
[12]
 we prepared Cy5.5 and Cy7.5 dyes bearing a single alcohol group. Then, 
esterification with squalenic acid allowed to obtain the final conjugates SQCy5.5 and 
SQCy7.5 (Scheme 1, Supporting Information). The emission spectrum of the SQCy5.5 
overlaps the absorption spectrum of the SQCy7.5 (Figure S13, Supporting Information), 
making them an ideal donor/acceptor FRET pair. In addition, the emission spectra of the two 
dyes are perfectly separated, and both emit in the so called "biological transparency NIR 
window " (i.e., NIR-I, 700-900 nm).
[13]
 Offering the opportunity to overcome the problems 
associated to tissue scattering and absorption observed at lower wavelengths (i.e., visible 
spectrum), these dyes can be efficiently applied for non-invasive in vivo imaging on 
preclinical animal models. 
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Figure 1. Structures of squalene bioconjugates used for the formulation of FRET NPs and 
schematic representation of the use of FRET signal to monitor NPs integrity status. 
 
 
 
Fluorescent FRET NPs have been prepared by nanoprecipitation in water of an ethanolic 
solution of SQGem with the two dyes (i.e., SQCy5.5 and SQCy7.5), followed by evaporation 
of the organic solvent under vacuum. While keeping constant the amount of SQGem (2 mg 
mL
-1
), optimization of the formulation was performed by tuning the weight percentage of the 
dyes with respect to the SQGem moiety. As displayed in Figure 2a, the emission signal of the 
acceptor (SQCy7.5) collected after excitation of the donor (SQCy5.5) at 640 nm increased 
with the total content of the dyes (weight SQdye/weight SQgem) in the formulation. Dilution 
of NPs in organic solvent was used to mimic the complete disassembly of the NPs. It resulted 
in disappearance of the SQCy7.5 emission and emergence of the strong SQCy5.5 signal 
(Figure 2b), which was proportional to the dye concentration. This indicated that the energy 
transfer signal could be observed only when NPs remained intact with the two dyes at a close 
distance. Accordingly, this FRET pair could be used to monitor the integrity status of the 
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nanoparticles. The highest FRET signal was obtained for the nanoformulation with the highest 
dye content (0.6% w/w of each). This formulation, from now indicated as FRET NPs, has thus 
been selected for all following studies. The loading of both dyes in the FRET NPs led to an 
overall quantum yield of 8.4%, (Figure S14, Supporting Information) which was close to the 
value measured for FRET nanoemulsion droplets encapsulating comparable dyes.
[10a]
 
Although lower compared to the value measured following dilution with ethanol (that is the 
donor quantum yield, 21.2%), this quantum yield assured that the brightness of the FRET NPs 
was high enough to monitor, in real time, the NPs integrity following their intravenous 
administration. 
NPs containing 0.6% w/w of SQCy5.5 (Donor NPs, D-NPs) or SQCy7.5 (Acceptor NPs, A-
NPs) only, were prepared as described above and used as controls (Figure S15, Supporting 
Information). The common squalene unit in SQGem, SQCy5.5 and SQCy7.5 allowed the self-
assembly of mixed bioconjugates as nanoparticles with a mean diameter of 139 nm, a narrow 
size distribution and a comparable surface charge (~ -45mV) (Table S1, Supporting 
Information). To mimic different percentages of FRET NPs integrity (expressed as % of intact 
FRET NPs with respect to the total dye amount in the mixture), various proportions of FRET 
NPs, D-NPs and A-NPs were blended, keeping constant the overall amount of dyes. As 
expected, a decrease in FRET NPs integrity %, was associated to a concentration dependent 
increase in the donor signal following excitation at 640 nm, (Figure S16, Supporting 
Information) which became similar to that of the D-NPs alone for the mixture corresponding 
to 0% integrity of FRET NPs (Figure S15b,c, Supporting Information). 
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Figure 2. Fluorescence emission spectra (excitation at 640 nm) of NPs formulated by tuning 
the % of dyes after dilution with (a) water or (b) ethanol. Each formulation contains the same 
amount of SQCy5.5 and SQCy7. The percentage of each dye with respect to the SQGem 
moiety is indicated in the figure legend. (c) Images of mixtures of FRET NPs mimicking 
different integrity % (excitation at 640 nm (emission collected at 695-770 nm (donor signal) 
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and 810-875 nm (FRET signal)). (d) Calibration curve A/(A+D) ratio vs NP integrity %. Data 
represent mean ± standard deviation (SD) (n=2). 
 
 
This behavior was then confirmed by imaging the NPs mixtures using an in vivo imaging 
system (IVIS
®
, PerkinElmer) after excitation at 640 nm (Figure 2c). Moving to the lowest % 
of FRET NPs integrity, variation of the pseudocolor toward the red (high signal) was 
observed in the donor emission filter, while the color changed from light blue to dark 
blue/violet (low values) in the FRET emission one. The image of fully disintegrated NPs 
(corresponding to a mixture of D-NPs and A-NPs only) matched that of D-NPs only, thus 
confirming that in the absence of FRET NPs integrity, no FRET signal could be detected. 
Following signal quantification, the so called FRET proximity ratio (i.e., A/(A+D)),
[14]
 
coinciding with the different FRET NPs integrity % was then calculated. By plotting this 
semi-quantitative measurement of the FRET efficiency versus the integrity percentage, it was 
then possible to construct a calibration curve of the FRET NPs integrity (Figure 2d), useful to 
assess their stability over time.  
This stability was then evaluated at 37°C after opportune dilution in (i) water, (ii) murine 
blood and (iii) ethanol (Figure 3). Dilution in organic solvent was used as a control for 
complete disintegration of FRET NPs and absence of energy transfer, which corresponded to 
a baseline value of the A/(A+D) ratio (around 0.1, Figure 3, white bars). In water, no 
modification of the FRET proximity ratio was detected until 6 h of incubation, while it 
progressively decreased after 24 h. Contrarily, a rapid reduction of the FRET efficiency was 
already observed after 35 minutes of incubation in blood and the value reached the baseline 
after only 4 h. According to the calibration curve, these results revealed that FRET NPs were 
still intact in water after 6 h and that only a minimal disintegration occurred after 24 h (84 ± 
7% integrity). Disintegration slowly continued but 60% of nanoparticles still remained intact 
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after 48 h incubation. On the contrary, the integrity of FRET NPs was only 30% at 2 h post 
incubation in blood. Afterwards, the signal was too low to be quantified. As expected, for D-
NPs incubated in the same media, the A/(A+D) ratio corresponded to the baseline value, thus 
clearly confirming that the FRET signal originated only from the transfer of energy between 
the two dyes being at close vicinity within the same nanoparticle (Figure S17a, Supporting 
Information). The physical mixture of D-NPs and A-NPs showed the same behaviour in water 
and ethanol, while a slight FRET signal appeared in blood (Figure S17b, Supporting 
Information). Being the two dyes loaded into separate NPs, such observation might be 
explained by a partitioning in blood components (e.g., albumin, lipoproteins)
[15]
 with few dye 
molecules coming close enough to trigger the energy transfer to occur. Nevertheless, the 
A/ A+D) ratio  alues were low  ≤ 0.2) and the pheno enon was only transient. 
Once verified that FRET NPs integrity could be monitored following the variation of the 
FRET efficiency, we applied it to detect in real time the integrity status of the NPs after 
intravenous administration in mice. In particular, we aimed at elucidating whether these 
nanoparticles could accumulate into the liver, in which form (intact or disassembled) and for 
how long, since severe liver injury consequent to hepatic accumulation of NPs represents a 
major toxicological issue. According, a prediction of the risk associated to the NPs exposure 
is crucial to shorten the translation of nanomedicines from the bench to the bedside. In this 
context, the FRET approach could represent a valuable tool to assess the in vivo fate of the 
SQGem NPs. 
 
 
 
     
10 
 
 
Figure 3. In vitro stability study of FRET NPs at 37 °C after dilution with (i) MilliQ
®
 water 
(blue bars), (ii) mouse blood (red bars) or (iii) ethanol (white bars). Results are expressed as 
mean ± standard deviation (SD) (n=2). (*** indicates p < 0.001, n.s. indicates no significant 
differences, by two-way Anova with a Tukey's multiple comparison post-test).  
 
 
Thus, mice have been injected with FRET NPs intravenously in the lateral tail vein and then 
imaged at regular time points. Following excitation at 640 nm, the FRET and Donor signals 
were collected on the 810-875 nm (acceptor channel) and 695-775 nm (donor channel) 
emission filters, respectively. The first image has been acquired at 35 minutes post injection. 
Then, the evolution of the signal has been monitored over time (Figure 4). The variation of 
the pseudocolor in the acquired images suggested a fast accumulation of the FRET NPs into 
the liver, which reached the maximum at 35 minutes. Importantly, the signal recorded for 
FRET NPs at the donor channel (Donor signal) was weaker compared to that of the control D-
NPs, whereas at the acceptor channel (FRET signal) the opposite was observed (Figure 4). 
This result clearly indicated that at 35 min post injection, FRET NPs preserved at least 
partially their integrity in the liver. On the contrary, after 2 h, the intensity increase at the 
donor channel was accompanied by the decrease at the FRET channel (Figure 4), so that the 
signals at the two channels became similar to those for the control D-NPs at 2 h (Figure S19, 
Supporting Information).ɸ
 
Thus, FRET NPs rapidly disassembled, leading to an increase in 
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the distance between donor and acceptor dyes and consequently a loss of the FRET signal. 
Then, the progressive decrease of all signals clearly indicated the elimination of the 
bioconjugates. As expected, according to NPs disintegration and elimination from the liver, 
the acceptor signal (collected on the 810-875 nm emission filter following excitation at 745 
nm) displayed a progressive decrease over time too (Figure S18, Supporting Information). 
Similar signal evolution was observed after injection of D-NPs and A-NPs alone (Figure S19 
and S20, Supporting Information). Control mice displayed negligible background signal 
(Figure S21, Supporting Information). 
Signal has been then quantified by tracing a region of interest at the level of the liver. In 
agreement with the acquired images, the signal collected at the donor channel, progressively 
increased, reaching the highest intensity at 2 h, and then decreased (solid green line) (Figure 
S22a, Supporting Information). No quantification has been possible after 6 h. On the contrary, 
for the FRET signal collected at the acceptor channel, the maximum value corresponded to 
the first acquisition at 35 minutes and then a reduction of the signal was measured (solid red 
line). D-NPs showed an analogous behaviour (green dashed line) (Figure S22a, Supporting 
Information). 
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Figure 4. In vivo representative images of one mouse after intravenous injection of FRET 
NPs or D-NPs Excitation at 640 nm and emission collection at 695-770 nm (donor signal) and 
810-875 nm (FRET signal). 
 
 
These results clearly demonstrated that SQGem NPs disassembled in the liver, as shown by 
FRET efficiency, (Figure S22b, Supporting Information) which peaked at 35 minutes 
(maximal accumulation of intact nanoparticles) and then dropped down after 2 h post 
injection. No FRET efficiency was measured following injection of D-NPs, thus confirming, 
once again, that the FRET signal originated only from the transfer of energy between the pair 
of FRET dyes into the same nanoparticle. According to these data, the integrity of the FRET 
NPs in the liver followed a kinetic similar to that observed in vitro in the blood, with around 
56% of intact NPs 35 minutes after injection and then a fast disintegration, leading to less than 
10% of NPs integrity at 2 h post administration. It has to be noted that only scarce information 
is instead available about long-term liver accumulation of biodegradable polymer NPs (e.g. 
poly(lactic-co-glycolic acid) (PLGA) NPs) despite their broad use in the drug delivery field. 
Indeed, most of the studies evaluated only a few hours post-administration, and the 
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monitoring mainly relied on the quantification of physically encapsulated drugs or fluorescent 
dyes.  hus, in case of dye  or drug) lea age, detection doesn’t sign necessarily the presence of 
intact or degraded nanoparticles.
[16]
 Regarding longer-term studies, a quantitative analysis of 
PLGA NPs accumulation and in vivo degradation,
[17]
 revealed that around 10% and 20% of 
the injected dose of respectively 200 nm and 500 nm NPs, was still present in the liver 7 days 
after injection. Moreover, silica and metal nanoparticles were intensively investigated and 
their long-term persistence raised concerns about potential chronic toxicity.
[7, 18]
 For instance 
after intravenous injection of silica NPs
[19]
 and gold NPs
[20]
 prolonged hepatic retention was 
observed for up to 1 and 2 months, respectively. CdSeTe quantum dots persisted in the liver 
for up to six months,
[21]
 while gold and superparamagnetic iron were detected even at 1 year 
post administration of iron oxide-coated gold nanoparticles.
[22]
 
In conclusion, the present study shows that the herein synthesized SQ-based FRET dyes 
allowed to shed light on the integrity of SQGem NPs after systemic administration. Results 
unambiguously revealed that these NPs could at least partially preserve their integrity at the 
initial accumulation in the liver. However, no persistent accumulation of NPs in the hepatic 
tissue was observed thus suggesting appropriate safety profile and absence of hepatic 
thesaurismoses, a frequent toxicological event in nanomedicine. This is in agreement with 
previous reports, where neither alterations of the of hepatic enzymes levels nor morphological 
damages were observed after intravenous administration of squalene-based NPs.
[6b, 23]
 On the 
whole these results would facilitate the future introduction of squalene-based nanomedicines 
into clinical settings. It has to be noted that application of these dyes to whole-body imaging 
in humans is still limited by the depth of penetration of the NIR-I light (less than 1 cm).
[24]
 
However, the development of new dyes, which emit at longer wavelengths (NIR-II region 
1000-1700 nm) in combination with advanced instruments endowed with higher sensitivity 
and resolution, is expected to allow deeper tissue penetration, in the near future. 
     
14 
 
Experimental Section  
Materials: Gemcitabine  2’,2’-difluorodeoxycitidine) hydrochloride was purchased from 
Sequoia Research Products Ltd. (Pangbourne, UK). 4-(N)-trinorsqualenoyl-gemcitabine 
(SQGem) was synthesized as previously described.
[4a]
 Reagents for the synthesis were 
purchased from Sigma Aldrich (France) and TCI Chemicals (France) and used without further 
purification. Analytical grade solvents were purchased from VWR Chemicals (France) or 
Sigma Aldrich (France). Ultrapure water was obtained with the MilliQ
®
 purification system 
(Merck Millipore, France). NMR spectra were recorded at 20°C on Bruker Avance III 400 
MHz and Bruker Avance III 500 MHz spectrometers. Mass spectra were obtained using an 
Agilent Q-TOF 6520 mass spectrometer. Flash chromatography was performed on PuriFlash 
430 (Interchim Inc). 
 
Formulation and characterisation of fluorescent SQGem nanoparticles (NPs): Fluorescent 
SQGem NPs were prepared according to the nanoprecipitation technique. Practically, a 
mixture of SQGem (4 mg mL
-1
 in ethanol), SQCy5.5 and SQCy7.5 (both at 0.5 mg mL
-1
 in 
ethanol) was added dropwise into MilliQ
®
 water under magnetic stirring (ethanol/water 0.5:1 
v/v). After solvent evaporation under vacuum (Rotavapor
®
 Buchi, France), an aqueous 
suspension of fluorescent NPs was obtained (final SQGem concentration: 2 mg mL
-1
). 
Keeping constant the concentration of SQGem, different formulations have been prepared by 
tuning the weight percentage of the dyes with respect to the SQGem. NPs selected for in vitro 
and in vivo studies contained 0.6% by weight of each dye (FRET NPs). Control formulations 
were prepared as described above using 0.6% of SQCy5.5 (donor NPs (D-NPs)) and 0.6% of 
SQCy7.5 (acceptor NPs (A-NPs)), respectively. Size and polydispersity index of the NPs 
were determined by dynamic light scattering at 25 °C (Zetasizer Nano ZS, Malvern 
Instruments, UK, 173° scattering angle). NP surface charge was investigated using the same 
apparatus, by zeta potential measurements at 25 °C after dilution with 1 mM NaCl solution 
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applying the Smoluchowski equation. All measurements were repeated at least three times. 
For in vitro and in vivo studies, NPs suspensions were brought to isotonicity using dextrose 
(5% w/w). 
 
Absorbance and fluorescence spectra: Absorbance spectra were measured with a UV-visible 
spectrophotometer (Lambda 25, Perkin Elmer, USA). Fluorescence emission spectra were 
measured with a spectrofluorometer (SPEX1681, Horiba, Japan) with an excitation 
wavelength of 640 nm (donor) or 760 nm (acceptor). Measurements were performed after 
opportune dilution of   s, which assured an absorbance ≤ 0.1 at the excitation wa elengths 
and a total dye concentration < 1 μM. For relative quantum yield measurement only, the 
absorption and emission spectra were recorded at RT (25 
o
C) on a Cary 400 Scan ultraviolet–
visible spectrophotometer (Varian) and FluoroMax-4 spectrofluorometer (Horiba JobinYvon), 
respectively. The emission spectra were corrected for the lamp fluctuations and the 
wavelength-dependent response of the detector. All fluorescence measurements were 
performed after opportune dilution of NPs (absorbance ≤ 0.1). The excitation wavelength was 
630 nm. Quantum yields were calculated using rhodamine 800 in ethanol (quantum yield = 
0.25) as a reference.
[25]
 
 
Fluorescence imaging settings and image analysis: Images were acquired using the IVIS 
Lumina
®
 LT Series III (PerkinElmer, USA). After excitation at 640 nm, the donor signal was 
recovered on the 695-770 nm emission filter (donor channel) and the FRET signal was 
recovered on the 810-875 nm emission filter (acceptor channel). Acceptor signal was 
recovered on the 810-875 nm emission filter (acceptor channel) after excitation at 745 nm. 
Images were processed using the Living Image software (PerkinElmer, USA). For 
quantification, a region of interest was automatically drawn around (i) the wells of the 96-well 
     
16 
 
plates (in vitro studies) or (ii) the mice liver (in vivo studies). Average radiant efficiency 
values (threshold of 5% and 30% for in vitro and in vivo images, respectively) have been used 
for quantification. The semi-quantitative measurement of the efficiency of the FRET signal 
(i.e., FRET proximity ratio)
[14]
 was calculated as A/(A+D) ratio. A and D corresponded to the 
fluorescence intensity of the acceptor (collected on the 810-875 nm emission filter) and donor 
(collected on the 695-770 nm emission filter) respectively, after excitation at 640 nm 
(i.e.,donor excitation).  
 
Animals: Four-week-old immunodeficient female mice (athymic nude) were purchased from 
Envigo Laboratory (France). Animals were housed in an appropriate animal care facility 
during the experimental period. Mice blood used for in vitro studies was obtained by cardiac 
puncture under deep terminal anesthesia with pentobarbital, and collected in VACUETTE
®
 
EDTA tubes (Greiner Bio-one). Experimental protocols were approved by the Animal Care 
Committee of the Université Paris-Sud in accordance with the principles of laboratory animal 
care and the French legislation.  
 
In vitro NPs disaggregation study: In order to mimic the disassembly of FRET NPs, mixtures 
of FRET NPs (dilution 1:2 with MilliQ
®
 water), D-NPs and A-NPs were prepared. 0% 
integrity corresponded to a mixture of D-NPs and A-NPs (ratio 1:1), 50% integrity 
corresponded to a mixture of diluted FRET NPs, D-NPs and A-NPs (ratio 0.5:0.25:0.25) and 
100% integrity corresponded to the diluted FRET NPs only. The overall concentration of the 
dyes was maintained constant. 70 µL of each mixture corresponding to different integrity % 
were loaded into a 96-well black plate and imaged using the Lumina system. Acquisition has 
been performed as previously described (see section Fluorescence imaging settings and image 
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analysis). Experiment was repeated two times. Results are expressed as mean ± standard 
deviation. 
Values of A/(A+D) ratio were then plotted versus the percentage of NPs integrity and data 
were fitted (SigmaPlot, Version 12) according to an exponential function (1) 
y= y0 + ae
bx
 
Where y0 = 0.1055, a=0.0152 and b=0.0391. 
 
In vitro stability study: D-NPs and FRET NPs (dilution 1:2 in MilliQ
®
 water) and a D-NPs/A-
NPs physical mixture (ratio 1:1) were diluted (1:6) with (i) MilliQ
®
 water, (ii) ethanol or (iii) 
mouse blood and incubated at 37 °C under stirring over a period of 48 h. Immediately after 
mixing (t=1 minute), and then at t=35 minutes (0.58 h), 2 h, 4 h, 6 h, 24 h and 48 h post 
incubation, 70 µl of each mixture was loaded in a 96-well black plate (Sigma Aldrich, France) 
and fluorescence signal was collected with the Lumina system (see section Fluorescence 
imaging settings and image analysis). The experiment was repeated twice in duplicate. 
Results are expressed as mean ± standard deviation. 
 
In vivo non-invasive imaging: 200 µL of FRET NPs, D-NPs or A-NPs were administered to 
athymic mice (n=6 for FRET and D-NPs, n=2 for A-NPs) by intravenous injection in the tail 
vein. At regular time intervals post injection, (t=35 minutes (0.58 h), 2 h, 4 h, 6 h, 24 h and 48 
h) mice were anesthetized with isoflurane and placed in ventral position in the IVIS Lumina
®
. 
Fluorescence images were recorded as described previously (see section Fluorescence 
imaging settings and image analysis) 
 
Statistical analysis. 
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Statistical analysis was performed with the Prism GraphPad 7.0 software. The significance 
was calculated using a two-way Anova method, with a Tukey's multiple comparison post-test 
(black asterisks in the figure) 95% confidence interval.  
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Supporting Information is available from the Wiley Online Library or from the author. 
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